Ability Biotherapeutics

The premier biotherapeutic targeting company
Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning artificial intelligence (AI) with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity.
The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics. We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need. To learn more, contact us at partnering@ability.bio.